A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
Status:
Recruiting
Trial end date:
2023-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and recommended Phase 2 dose (RP2D) of
JNJ-67856633 and ibrutinib in combination in participants with B cell non-Hodgkin lymphoma
(NHL) and chronic lymphocytic leukemia (CLL) in Part A (Dose Escalation) and to evaluate
safety of JNJ-67856633 and ibrutinib in combination, at the RP2D regimen in Part B (Cohort
Expansion).